Evaluation of a ddPCR technology for the SARS-CoV-2 detection based on different types of samples in cancer patients with suspicion of COVID-19 (symptomatic)

{
"level_sex_clusion_I": [],
"level_age_clusion_I": [],
"level_type_clusion_I": [
"Patients population"
],
"level_type_clusion_other": "",
"clusion_I": "1. Age ≥ 18 years on the day of signing informed consent. 2. Confirmed diagnosis of any type of solid or hematologic tumor. 3. Ongoing anticancer treatment at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) 4. Suspicion of COVID-19 infection. Patients must not have underwent diagnostic test and\/or chest imaging before inclusion. * At least one of the following clinical symptoms: fever (>38°C), dry cough, fatigue, pulmonary involvement (febrile respiratory infection or respiratory difficulties), pharyngalgia, headaches, myalgia, gastrointestinal symptoms including abdominal pain and diarrhea, anosmia and agueusia, radiological signs of pneumonia as described by Shi et al. 5. Covered by a medical\/health insurance. 6. Signed and dated informed consent form.",
"clusion_E": ""
}